Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
The UK medical research charity LifeArc has sold most of its royalty rights for the antibody pembrolizumab to the Canada Pension Plan Investment Board for $1.3 billion. LifeArc got the royalty for helping develop the antibody with Organon, which Merck & Co. later acquired. Pembrolizumab, now marketed by Merck as Keytruda, brought in sales of $7.2 billion last year. LifeArc chairman John Stageman describes the deal as “a once-in-a-generation opportunity.”
This article has been sent to the following recipient: